- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06477614 | Anti-cancer DC Cell Vaccination to Treat Solid Tumors | recruiting | Phase 1 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06478108 | Interventional Software for Multi-immunotherapy of Solid Tumors | recruiting | Phase 2 / Phase 3 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT00875004 | Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors(PLATON) | terminated | N/A | 27 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06195293 | Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06195384 | Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03778814 | TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04803318 | Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04842812 | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors | recruiting | Phase 1 | 40 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05779917 | Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06473948 | To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects | unknown | Phase 1 | 27 | JemincareINDUSTRY | 0 | Jun 25, 2024 | clinicaltrials |
| NCT06469268 | Development and Application Study of ePRO Software for Managing Cancer Patients Throughout the Treatment Period | unknown | N/A | 100 | Shikai WuOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT03617692 | Cannabis Use in Cancer Patients | completed | — | 27 | University of Colorado, DenverOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT05054348 | First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors | completed | Phase 1 | 91 | Immune-Onc TherapeuticsINDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05309187 | Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors | completed | Phase 1 | 22 | Immune-Onc TherapeuticsINDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06136065 | 68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors(FAPI) | unknown | Phase 2 | 100 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06433726 | A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Chengdu Baiyu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT05605197 | U87 CART in Treatment of Advanced Solid Tumor | unknown | Phase 1 | 12 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT04092673 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies(Zotatifin) | unknown | Phase 1 / Phase 2 | 30 | Effector TherapeuticsINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT03004755 | The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study(PEACE) | unknown | — | 500 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06404528 | Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours | recruiting | N/A | 300 | Wuxi People's HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05868174 | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | recruiting | Phase 1 | 36 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT04402606 | Study on Skin Toxicities Induced by Cancer Treatments(DERMACLIC) | completed | N/A | 292 | Institut CurieOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT02054741 | Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer | completed | N/A | 733 | Supriya MohileOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02107443 | Improving Communication in Older Cancer Patients and Their Caregivers(COACH) | completed | N/A | 546 | Supriya MohileOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06348290 | Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects | unknown | Phase 1 | 72 | JemincareINDUSTRY | 0 | Apr 4, 2024 | clinicaltrials |
| NCT04901806 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | terminated | Phase 1 | 29 | Pyramid BiosciencesINDUSTRY | 11 | Mar 28, 2024 | clinicaltrials |
| NCT04200963 | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | completed | Phase 1 | 78 | Ikena OncologyINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03914872 | Expanded Access Neoantigen Vaccine in Solid Tumors | no longer available | — | — | Washington University School of MedicineOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT00020371 | BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06277804 | A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor | not yet recruiting | Phase 1 | 48 | LetolabINDUSTRY | 0 | Feb 26, 2024 | clinicaltrials |
| NCT04892043 | Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 5 | SQZ BiotechnologiesINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05078593 | A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma | completed | Phase 1 | 18 | Shanghai Henlius BiotechINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05357898 | Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 20 | SQZ BiotechnologiesINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06075849 | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | unknown | Phase 1 | 30 | Panolos BioscienceINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03728179 | RACIN in Patients With Advanced TIL-negative Solid Tumors(RACIN) | completed | Phase 1 | 40 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT00930332 | Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain | terminated | Phase 1 | 8 | NCIC Clinical Trials GroupNETWORK | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04842630 | A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors | terminated | Phase 1 | 11 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05400265 | Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor | completed | Phase 1 | 9 | Shanghai Henlius BiotechINDUSTRY | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03209401 | Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies | terminated | Phase 1 | 23 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06240767 | Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils | unknown | Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06232863 | A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer | unknown | Phase 1 | 24 | Zhuhai Beihai Biotech Co., LtdINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05099536 | 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | 3D Medicines (Beijing) Co., Ltd.INDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05695638 | Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment | recruiting | — | 3,000 | Morten LadekarlOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT04983810 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Jan 25, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT05388487 | Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors | unknown | Phase 1 | 54 | HighField Biopharmaceuticals CorporationINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 27, 2024source: clinicaltrials